Summary
Only a minority of extracted claims are supported by the provided label; the majority of beverage-related and ancillary claims are not supported by the FDA-approved prescribing information.
Category Scores
Accurate Statements
Food does not change absorption of pregabalin.
2.1
It can be taken with or without meals.
2.1
Swallow the capsule whole with a full glass of liquid at the same times each day.
2.1
Unsupported Statements
Lyrica (pregabalin) can be taken with water.
Not supported by the label; label states administration with or without food, but does not specify beverage-specific guidance.
Lyrica (pregabalin) can be taken with juice.
Not supported by the label; beverage-specific guidance is not provided.
Lyrica (pregabalin) can be taken with any non-alcoholic beverage.
Not supported by the label; no beverage-specific guidance.
The medication does not interact with these drinks in a way that affects its absorption or safety.
Not supported; label indicates minimal metabolic interactions in general, but does not provide beverage-specific interaction data.
The drug’s absorption stays consistent whether it is swallowed with water or with common soft drinks.
Not supported; label does not provide beverage-specific absorption data beyond 'with or without food.'
No clinically significant change in blood levels occurs when Lyrica is mixed with fruit juice or soda.
Not supported; label does not provide study data on juice/soda co-administration.
Patients do not need to adjust timing or dose because of drinking mixed with water or soft drinks.
Not supported; label addresses dosing adjustments for renal function, not beverage co-ingestion.
Caffeine does not alter Lyrica’s effectiveness.
Not supported; no label data on caffeine effects.
Caffeine does not increase side effects.
Not supported; no label data on caffeine interactions.
Patients who normally consume coffee or tea can continue without special restrictions.
Not supported; no label guidance on coffee/tea restrictions.
Grapefruit juice does not meaningfully affect pregabalin.
Not supported; label provides no data on grapefruit interactions.
No non-alcoholic beverage carries a documented warning for use with Lyrica.
Not supported; absence of beverage-specific warnings is not established in the label excerpt.
The expiration of the key U.S. patent for Lyrica expired in 2019.
Not supported; patent status is not part of the prescribing information provided.
The expiration of the key U.S. patent allowed generic pregabalin to enter the market.
Not supported; patent status is not part of the prescribing information provided.
Multiple manufacturers, including Teva, Mylan, and Sun Pharma, now produce generic versions.
Not supported; generic market details are not part of the provided prescribing information.
Contradictions
Important Omissions
Beverage-specific administration guidance (water/juice/coffee-related considerations) is not described beyond 'with or without food.'
Importance:
Moderate
Patents and generic-market status are not part of the prescribing information and thus not addressed in the label.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
Label indicates pregabalin is eliminated renally with minimal metabolism and terefore, beverage-specific claims are not described; no evident safety risk from speculative beverage combinations is indicated by the label.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Beverage- and ad libitum-related claims are largely unsupported by the label.
Suggested Improvement
Limit statements to label-supported administration guidance (with/without food), dosing considerations (renal function), and pharmacokinetic data; avoid beverage-specific interactions or effects unless supported by the label.